OPKO Health (OPK) Q3 2024 earnings summary

Executive summary

• Completed sale of select BioReference Health assets to Labcorp for $237.5 million, streamlining operations and focusing on core diagnostics, with a $121.5 million gain recognized.

• Expanded BARDA contract for ModeX, increasing total value to $110 million, supporting COVID-19 and influenza antibody development.

• Launched a $100 million share repurchase program, retiring 23.6 million shares for $36.8 million through early November.

• Issued $250 million in senior secured notes and $230 million in 2029 Convertible Notes, using proceeds for debt repayment and share repurchases.

• Advanced clinical pipeline with MDX2001 Phase 1 trial enrollment and promising preclinical results for an oral oxyntomodulin analog targeting obesity and metabolic disorders.

Financial highlights

• Q3 2024 total revenue was $173.6 million, down from $178.6 million year-over-year; net income was $24.9 million ($0.03 per diluted share), reversing a net loss of $84.5 million in Q3 2023.

• Operating income for Q3 2024 was $14.2 million, up from a $64.4 million loss in Q3 2023, driven by the BioReference asset sale gain.

• Cash, cash equivalents, and restricted cash totaled $420.1 million at September 30, 2024, up from $95.9 million at year-end 2023.

• Repurchased 79 million shares YTD, about 10% of shares outstanding as of January 1.

• Q3 2024 diagnostic segment revenue: $121.3 million (down from $131.7 million in Q3 2023); pharmaceutical segment revenue: $39.1 million (down from $40.7 million year-over-year).

Outlook and guidance

• Targeting break-even run rate for diagnostics by year-end and positive cash flow and profitability in 2025.

• Q4 2024 revenue guidance: $155–$160 million; costs and expenses: $200–$210 million (excluding non-recurring restructuring costs).

• Gross margin targets above 27% for remaining business; additional $20 million annualized cost savings initiative underway.

• R&D expected at $28–$34 million in Q4, with $5–$8 million offset by BARDA funding.

• Management expects BARDA funding to support ModeX's antibody development through February 2028, with $96 million in remaining performance obligations.